MoonLake Immunotherapeutics (MLTX)
52.02
+2.20
(+4.41%)
USD |
NASDAQ |
Nov 21, 16:00
52.02
0.00 (0.00%)
After-Hours: 20:00
MoonLake Immunotherapeutics Enterprise Value: 2.655B for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 2.655B |
| November 19, 2024 | 2.624B |
| November 18, 2024 | 2.575B |
| November 15, 2024 | 2.593B |
| November 14, 2024 | 2.824B |
| November 13, 2024 | 2.733B |
| November 12, 2024 | 2.786B |
| November 11, 2024 | 2.912B |
| November 08, 2024 | 2.779B |
| November 07, 2024 | 2.709B |
| November 06, 2024 | 2.760B |
| November 05, 2024 | 2.517B |
| November 04, 2024 | 2.440B |
| November 01, 2024 | 2.462B |
| October 31, 2024 | 2.440B |
| October 30, 2024 | 2.477B |
| October 29, 2024 | 2.552B |
| October 28, 2024 | 2.543B |
| October 25, 2024 | 2.458B |
| October 24, 2024 | 2.426B |
| October 23, 2024 | 2.451B |
| October 22, 2024 | 2.540B |
| October 21, 2024 | 2.604B |
| October 18, 2024 | 2.599B |
| October 17, 2024 | 2.545B |
| Date | Value |
|---|---|
| October 16, 2024 | 2.610B |
| October 15, 2024 | 2.540B |
| October 14, 2024 | 2.596B |
| October 11, 2024 | 2.599B |
| October 10, 2024 | 2.477B |
| October 09, 2024 | 2.520B |
| October 08, 2024 | 2.656B |
| October 07, 2024 | 2.775B |
| October 04, 2024 | 2.999B |
| October 03, 2024 | 2.792B |
| October 02, 2024 | 2.780B |
| October 01, 2024 | 2.774B |
| September 30, 2024 | 2.692B |
| September 27, 2024 | 2.596B |
| September 26, 2024 | 2.720B |
| September 25, 2024 | 2.685B |
| September 24, 2024 | 2.902B |
| September 23, 2024 | 2.974B |
| September 20, 2024 | 2.888B |
| September 19, 2024 | 2.867B |
| September 18, 2024 | 2.830B |
| September 17, 2024 | 2.696B |
| September 16, 2024 | 2.633B |
| September 13, 2024 | 2.706B |
| September 12, 2024 | 2.699B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
132.19M
Minimum
Jun 30 2022
3.368B
Maximum
Feb 12 2024
1.551B
Average
2.029B
Median
Jun 04 2024
Enterprise Value Benchmarks
| Novartis AG | 222.52B |
| AC Immune SA | 132.89M |
| CRISPR Therapeutics AG | 2.098B |
| Addex Therapeutics Ltd | 3.670M |
| NLS Pharmaceutics Ltd | 13.71M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -35.39M |
| Total Expenses (Quarterly) | 43.11M |
| EPS Diluted (Quarterly) | -0.56 |
| Earnings Yield | -2.44% |